Weight LossLegally CompoundedFDA Approved

Semaglutide

About

About Semaglutide

A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.

Science

Mechanism of Action

Semaglutide binds to and activates the GLP-1 receptor (GLP-1R), a GPCR expressed in the pancreas, brain, gut, heart, and kidneys. In the pancreas, GLP-1R activation stimulates glucose-dependent insulin secretion and suppresses glucagon. In the brain (hypothalamus and brainstem), it reduces appetite and increases satiety. Gastric emptying is slowed, contributing to reduced caloric intake. The net effect is significant weight loss and improved glycemic control.

Dosing

Typical Protocol

Week 1–4: 0.25 mg subcutaneously once weekly. Week 5–8: 0.5 mg once weekly. Week 9–12: 1.0 mg once weekly. Maintenance: 1.0–2.4 mg once weekly (titrate based on tolerability and response). Contraindications include personal/family history of MEN2, medullary thyroid carcinoma, or pancreatitis.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Legally Compounded

This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.

Evidence

Evidence Tier

FDA Approved

Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.